The study showed that SGLT2 inhibitor was associated with a significant reduction in eGFR decline (difference in slope for SGLT2 inhibitors vs other glucose-lowering drugs of 1.53 mL/min/1.73 m2, 95% CI 1.34–1.72, P < 0.0001) and that, during follow-up (mean 14.9 months), patients taking SGLT2 inhibitors had a significantly lower rate of the composite kidney outcome (50% eGFR decline or kidney failure). Here, SLC5A2 is linked to kidney failure.